FMC Heads Into Earnings With an Activist on the Register and Bears in Control

FMC Corporation reports third-quarter results today with one of the most charged ownership and positioning setups in the agricultural chemicals sector.

The most newsworthy fact about FMC right now is structural: Tessenderlo Group NV filed a Schedule 13D in late September, disclosing a 20% stake in the company. A 13D signals activist or strategic intent, not a passive investment. That filing sits alongside a stock that has lost nearly half its value in the past month alone, closing at $4.75 on Thursday after a 48% decline over 30 days. The 6.3% bounce on October 29 offered some relief, but the one-week reading is still negative at minus 5.4%. As with all 13D/G disclosures, the Tessenderlo stake is as-last-disclosed around the 5% threshold; the position may have changed since the September 25 filing.

Short sellers have been adding exposure into this weakness. Short interest has climbed to nearly 25% of the free float, up 10% over the past week, making this one of the more heavily shorted names in the sector. Despite the size of that short position, the borrow market remains surprisingly loose: availability is running at 356% of short interest, meaning there are more than three shares available to lend for every one currently borrowed. Cost to borrow is a modest 0.53%. That combination tells you the short thesis is driven by fundamental pessimism rather than a technical squeeze setup. Options positioning confirms the defensive lean: the put/call ratio is 0.71, well above its 20-day average of 0.42 and close to its 52-week high of 0.76, roughly 1.6 standard deviations above recent norms.

The analyst community has moved decisively negative in the run-up. Over the past two weeks, Jefferies downgraded FMC to Hold from Buy while slashing its target from $14 to $5, and Citigroup halved its target from $12 to $6 while staying at Neutral. Barclays already carried an Underweight and cut to $4. The mean price target across the group is $8.71, still roughly 83% above the current price, but that figure is being dragged up by outliers including a lone Overweight from Keybanc initiated in September at $16 and a $12 Outperform from Mizuho. The broad direction of travel is unmistakably lower. The bull case rests on management's confidence in delivering approximately $600 million of second-half EBITDA, aided by Latin America seasonal demand and post-channel-inventory volume recovery. Bears point to a 9% year-over-year price decline in the first quarter, below-consensus second-quarter guidance, and intensifying competition in Brazil.

On the ownership side, the picture is complicated further by BlackRock trimming its stake to 12.4% from 15.5%, as disclosed in an October 27 filing, while State Street and American Century have both added materially in recent months. ORTEX also puts the probability of FMC being deleted from the S&P SmallCap 600 at 57% at the December quarterly review, driven by its market cap of $739 million sitting within range of the exit threshold at $638 million. At 6.2% daily volatility, the stock only needs to fall 13.7% to cross that line. A deletion would require index trackers to sell an estimated $88 million of stock, equivalent to roughly four days of normal trading volume, a mechanical selling flow that has no fundamental signal but is real nonetheless.

Today's print is less a test of whether volumes are recovering and more a referendum on whether management's second-half confidence was warranted, and on what strategic posture Tessenderlo actually intends.